DSGN Form 4: Director-affiliated funds sell 562,627 shares at $5.25

Q: What transactions did William Arsani report on the Form 4 for DSGN?

The Form 4 reports two sales on 08/13/2025: 345,000 shares sold by Logos Global Master Fund LP and 217,627 shares sold by Logos Opportunities Fund II LP, each at $5.25 per share.

Q: How many shares do the funds beneficially own after the reported transactions?

After the sales the filing reports 2,655,000 shares beneficially owned by Logos Global Master Fund LP and 1,000,000 shares beneficially owned by Logos Opportunities Fund II LP.

[Form 4] Design Therapeutics, Inc. Insider Trading Activity

Filing Impact

(High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Design Therapeutics director William Arsani reported sales of company common stock on 08/13/2025. The Form 4 shows two dispositions executed at $5.25 per share: 345,000 shares sold by Logos Global Master Fund LP and 217,627 shares sold by Logos Opportunities Fund II LP. After the sales, the filing reports 2,655,000 shares beneficially owned by Logos Global Master Fund LP and 1,000,000 shares beneficially owned by Logos Opportunities Fund II LP. Arsani is identified as a director and the filing disclaims direct beneficial ownership except to the extent of a pecuniary interest through the reported funds. The form is signed by an attorney-in-fact on 08/14/2025.

Positive

Transparent disclosure of insider-related sales with specific share counts and prices
Post-transaction holdings disclosed for both Logos Global Master Fund LP and Logos Opportunities Fund II LP
Reporting person identified as a director and relationships to the funds are clearly explained

Negative

Insider-affiliated funds sold a combined 562,627 shares, reducing holdings at the reported price of $5.25 per share

Insights

TL;DR: Director-affiliated funds disposed of a combined 562,627 shares at $5.25, and substantial holdings remain in each fund.

The transaction is a clear, disclosed sale of company common stock by funds managed by the reporting person. Combined disposals total 562,627 shares at $5.25 per share. The filing provides post-transaction beneficial ownership levels for each fund: 2,655,000 and 1,000,000 shares, respectively. This Form 4 follows Section 16 reporting requirements and includes standard disclaimers that the reporting person disclaims direct beneficial ownership except for pecuniary interest. No derivative transactions or additional compensatory details are reported in this filing.

TL;DR: Routine disclosure of director-related fund sales with standard beneficial ownership disclaimers; no governance changes disclosed.

The filing identifies William Arsani as a director and shows sales executed through entities for which he is managing member or associated advisor. The explanation sections attach standard GP/advisor relationships and disclaimers of direct ownership. There are no indications of leadership changes, related-party compensation shifts, or amendments to governance arrangements within this filing. Signature is provided by an attorney-in-fact, consistent with permitted practice.

08/14/2025 - 04:15 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

William Arsani

(Last)

(First)

(Middle)

C/O DESIGN THERAPEUTICS, INC.

6005 HIDDEN VALLEY ROAD, SUITE 110

(Street)

CARLSBAD

92011

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Design Therapeutics, Inc. [ DSGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/13/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	08/13/2025		S		345,000	D	$5.25	2,655,000	I	By Logos Global Master Fund LP⁽¹⁾
Common Stock	08/13/2025		S		217,627	D	$5.25	1,000,000	I	By Logos Opportunities Fund II LP⁽²⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Logos GP LLC ("Fund GP") is the general partner of Logos Global Master Fund LP (the "Fund"). The Reporting Person is the Managing Member of Fund GP. The Reporting Person disclaims beneficial ownership of these securities except to the extent of Reporting Person's pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

2. Logos Global Management LP is the investment advisor of private funds, including Logos Opportunities Fund II LP ("LOF II"). Logos Opportunities GP LLC ("GP I") is the general partner of LOF II. The Reporting Person is the Managing Member of GP I. The Reporting Person disclaims beneficial ownership of these securities except to the extent of Reporting Person's pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

	/s/ Mustapha Parekh, Attorney-in-Fact	08/14/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

What transactions did William Arsani report on the Form 4 for DSGN?

The Form 4 reports two sales on 08/13/2025: 345,000 shares sold by Logos Global Master Fund LP and 217,627 shares sold by Logos Opportunities Fund II LP, each at $5.25 per share.

How many shares do the funds beneficially own after the reported transactions?

After the sales the filing reports 2,655,000 shares beneficially owned by Logos Global Master Fund LP and 1,000,000 shares beneficially owned by Logos Opportunities Fund II LP.

What is William Arsani鈥檚 relationship to the entities that sold DSGN shares?

The filing states the Reporting Person is the Managing Member of Logos GP LLC (general partner of Logos Global Master Fund LP) and Managing Member of Logos Opportunities GP LLC (general partner of LOF II), and disclaims direct ownership except for pecuniary interest.

Did the Form 4 disclose any derivative transactions or option exercises?

No. Table II (derivative securities) contains no reported transactions; only non-derivative common stock sales are listed.

When was the Form 4 signed and who signed it?

The form is signed by /s/ Mustapha Parekh, Attorney-in-Fact, dated 08/14/2025.

AG真人官方

[Form 4] Design Therapeutics, Inc. Insider Trading Activity

Insights

FAQ

What transactions did William Arsani report on the Form 4 for DSGN?

How many shares do the funds beneficially own after the reported transactions?

What is William Arsani鈥檚 relationship to the entities that sold DSGN shares?

Did the Form 4 disclose any derivative transactions or option exercises?

When was the Form 4 signed and who signed it?

NASDAQ:DSGN

DSGN Rankings

DSGN Latest News

DSGN Latest SEC Filings

DSGN Stock Data

AG真人官方

Trending News

[Form 4] Design Therapeutics, Inc. Insider Trading Activity

Insights

Securities Analyst neutral

Corporate Governance Expert neutral

FAQ

What transactions did William Arsani report on the Form 4 for DSGN?

How many shares do the funds beneficially own after the reported transactions?

What is William Arsani鈥檚 relationship to the entities that sold DSGN shares?

Did the Form 4 disclose any derivative transactions or option exercises?

When was the Form 4 signed and who signed it?

NASDAQ:DSGN

DSGN Rankings

DSGN Latest News

DSGN Latest SEC Filings

DSGN Stock Data